Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69


PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.

Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C.

Nat Med. 2003 Nov;9(11):1413-7. Epub 2003 Oct 19.


Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.

Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9468-73. Epub 2002 Jun 20.


DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.

Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA.

Blood. 2010 Jan 21;115(3):653-6. doi: 10.1182/blood-2007-08-109009. Epub 2009 Nov 19.


DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.

Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Omidvar N, Tekin N, Bernasconi E, Sicre F, Schlageter MH, Chopin M, Noguera ME, West R, Abu A, Mathews V, Pla M, Fenaux P, Chomienne C, Padua RA.

Oncotarget. 2015 Oct 20;6(32):32494-508. doi: 10.18632/oncotarget.5572.


Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms.

Pollock JL, Lane AA, Schrimpf K, Ley TJ.

Haematologica. 2005 Aug;90(8):1042-9.


C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.

Duprez E, Wagner K, Koch H, Tenen DG.

EMBO J. 2003 Nov 3;22(21):5806-16.


[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.


Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.

Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H.

Nat Med. 2008 Dec;14(12):1333-42. doi: 10.1038/nm.1891. Epub 2008 Nov 23. Erratum in: Nat Med. 2009 Jan;15(1):117.


Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.

Vitoux D, Nasr R, de The H.

Int J Biochem Cell Biol. 2007;39(6):1063-70. Epub 2007 Mar 21. Review.


All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24.


Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.

Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL, Gravekamp C.

Breast Cancer Res Treat. 2005 May;91(1):19-28.


High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ.

Blood. 2003 Sep 1;102(5):1857-65. Epub 2003 May 15.


Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.

Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M.

Haematologica. 2007 Mar;92(3):323-31.


Acute promyelocytic leukemia: a view from a mouse.

Kogan SC.

Blood Cells Mol Dis. 2000 Dec;26(6):620-5. Review.


Alteration in the cellular response to retinoic acid of a human acute promyelocytic leukemia cell line, UF-1, carrying a patient-derived mutant PML-RARalpha chimeric gene.

Sato A, Imaizumi M, Hoshi Y, Rikiishi T, Fujii K, Kizaki M, Kagechika H, Kakizuka A, Hayashi Y, Iinuma K.

Leuk Res. 2004 Sep;28(9):959-67.


Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.

Gupta V, Yib QL, Brandwein J, Chun K, Lipton JH, Messner H, Schuh AC, Wells RA, Minden MD, Kamel-Reidc S.

Leuk Lymphoma. 2004 Mar;45(3):469-80.


PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.

Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M.

Cancer Biol Ther. 2007 Dec;6(12):1967-77. Epub 2007 Sep 4.


A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.

Naeem M, Harrison K, Barton K, Nand S, Alkan S.

Eur J Haematol. 2006 Feb;76(2):164-6.


Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: biomarker of long-term drug efficacy.

Pokorna K, Le Pogam C, Chopin M, Balitrand N, Reboul M, Cassinat B, Chomienne C, Padua RA, Pla M.

Mol Cell Probes. 2013 Feb;27(1):1-5. doi: 10.1016/j.mcp.2012.08.001. Epub 2012 Aug 11.


Benzodithiophenes induce differentiation and apoptosis in human leukemia cells.

Jing Y, Hellinger N, Xia L, Monks A, Sausville EA, Zelent A, Waxman S.

Cancer Res. 2005 Sep 1;65(17):7847-55.

Supplemental Content

Support Center